nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—prostate cancer—Betamethasone—hematologic cancer	0.191	0.5	CpDpCtD
Fentanyl—prostate cancer—Dexamethasone—hematologic cancer	0.191	0.5	CpDpCtD
Fentanyl—ABCB1—hematologic cancer	0.0673	1	CbGaD
Fentanyl—ABCB1—Lenalidomide—hematologic cancer	0.0123	0.0372	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0118	0.0358	CbGbCtD
Fentanyl—CYP3A7—Ifosfamide—hematologic cancer	0.0118	0.0358	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0113	0.0342	CbGbCtD
Fentanyl—CYP3A7—Imatinib—hematologic cancer	0.0113	0.0342	CbGbCtD
Fentanyl—CYP3A5—Daunorubicin—hematologic cancer	0.0111	0.0335	CbGbCtD
Fentanyl—CYP3A5—Thalidomide—hematologic cancer	0.0101	0.0305	CbGbCtD
Fentanyl—CYP3A5—Teniposide—hematologic cancer	0.00963	0.0291	CbGbCtD
Fentanyl—CYP3A5—Ifosfamide—hematologic cancer	0.00888	0.0268	CbGbCtD
Fentanyl—CYP3A5—Imatinib—hematologic cancer	0.00849	0.0256	CbGbCtD
Fentanyl—CYP3A4—Bexarotene—hematologic cancer	0.00737	0.0223	CbGbCtD
Fentanyl—ABCB1—Daunorubicin—hematologic cancer	0.00721	0.0218	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00707	0.0214	CbGbCtD
Fentanyl—CYP3A7—Irinotecan—hematologic cancer	0.00707	0.0214	CbGbCtD
Fentanyl—ABCB1—Alitretinoin—hematologic cancer	0.00706	0.0213	CbGbCtD
Fentanyl—CYP3A4—Busulfan—hematologic cancer	0.00685	0.0207	CbGbCtD
Fentanyl—CYP3A4—Lomustine—hematologic cancer	0.00685	0.0207	CbGbCtD
Fentanyl—CYP3A5—Dasatinib—hematologic cancer	0.00682	0.0206	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00618	0.0187	CbGbCtD
Fentanyl—CYP3A7—Vincristine—hematologic cancer	0.00618	0.0187	CbGbCtD
Fentanyl—CYP3A4—Thiotepa—hematologic cancer	0.00611	0.0185	CbGbCtD
Fentanyl—ABCB1—Imatinib—hematologic cancer	0.00552	0.0167	CbGbCtD
Fentanyl—CYP3A5—Irinotecan—hematologic cancer	0.0053	0.016	CbGbCtD
Fentanyl—ABCB1—Nilotinib—hematologic cancer	0.00502	0.0152	CbGbCtD
Fentanyl—ABCB1—Vinorelbine—hematologic cancer	0.00498	0.015	CbGbCtD
Fentanyl—CYP3A4—Methoxsalen—hematologic cancer	0.00475	0.0143	CbGbCtD
Fentanyl—CYP3A7—Dexamethasone—hematologic cancer	0.00465	0.0141	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00465	0.0141	CbGbCtD
Fentanyl—CYP3A5—Vincristine—hematologic cancer	0.00463	0.014	CbGbCtD
Fentanyl—CYP3A4—Bortezomib—hematologic cancer	0.00452	0.0136	CbGbCtD
Fentanyl—ABCB1—Dasatinib—hematologic cancer	0.00444	0.0134	CbGbCtD
Fentanyl—ABCB1—Mitoxantrone—hematologic cancer	0.00438	0.0132	CbGbCtD
Fentanyl—CYP3A4—Daunorubicin—hematologic cancer	0.00432	0.0131	CbGbCtD
Fentanyl—CYP3A5—Etoposide—hematologic cancer	0.00425	0.0128	CbGbCtD
Fentanyl—ABCB1—Betamethasone—hematologic cancer	0.00391	0.0118	CbGbCtD
Fentanyl—ABCB1—Gemcitabine—hematologic cancer	0.00387	0.0117	CbGbCtD
Fentanyl—ABCB1—Prednisolone—hematologic cancer	0.00385	0.0116	CbGbCtD
Fentanyl—CYP3A4—Cytarabine—hematologic cancer	0.00381	0.0115	CbGbCtD
Fentanyl—CYP3A4—Teniposide—hematologic cancer	0.00375	0.0113	CbGbCtD
Fentanyl—ABCB1—Prednisone—hematologic cancer	0.00364	0.011	CbGbCtD
Fentanyl—CYP3A5—Dexamethasone—hematologic cancer	0.00349	0.0105	CbGbCtD
Fentanyl—CYP3A4—Ifosfamide—hematologic cancer	0.00346	0.0105	CbGbCtD
Fentanyl—ABCB1—Irinotecan—hematologic cancer	0.00345	0.0104	CbGbCtD
Fentanyl—CYP3A4—Imatinib—hematologic cancer	0.00331	0.01	CbGbCtD
Fentanyl—CYP3A4—Ruxolitinib—hematologic cancer	0.00312	0.00942	CbGbCtD
Fentanyl—ABCB1—Vinblastine—hematologic cancer	0.00307	0.00927	CbGbCtD
Fentanyl—ABCB1—Vincristine—hematologic cancer	0.00302	0.00911	CbGbCtD
Fentanyl—CYP3A4—Nilotinib—hematologic cancer	0.00301	0.00909	CbGbCtD
Fentanyl—CYP3A4—Vinorelbine—hematologic cancer	0.00298	0.00901	CbGbCtD
Fentanyl—ABCB1—Cisplatin—hematologic cancer	0.00281	0.0085	CbGbCtD
Fentanyl—ABCB1—Etoposide—hematologic cancer	0.00276	0.00835	CbGbCtD
Fentanyl—CYP3A4—Triamcinolone—hematologic cancer	0.00273	0.00824	CbGbCtD
Fentanyl—CYP3A4—Dasatinib—hematologic cancer	0.00266	0.00803	CbGbCtD
Fentanyl—CYP3A4—Mitoxantrone—hematologic cancer	0.00263	0.00793	CbGbCtD
Fentanyl—CYP3A4—Betamethasone—hematologic cancer	0.00234	0.00707	CbGbCtD
Fentanyl—CYP3A4—Prednisolone—hematologic cancer	0.00231	0.00698	CbGbCtD
Fentanyl—ABCB1—Dexamethasone—hematologic cancer	0.00227	0.00686	CbGbCtD
Fentanyl—CYP3A4—Prednisone—hematologic cancer	0.00218	0.00659	CbGbCtD
Fentanyl—CYP3A4—Irinotecan—hematologic cancer	0.00207	0.00625	CbGbCtD
Fentanyl—ABCB1—Doxorubicin—hematologic cancer	0.00188	0.00569	CbGbCtD
Fentanyl—CYP3A4—Vinblastine—hematologic cancer	0.00184	0.00555	CbGbCtD
Fentanyl—ABCB1—Methotrexate—hematologic cancer	0.00183	0.00552	CbGbCtD
Fentanyl—CYP3A4—Vincristine—hematologic cancer	0.00181	0.00546	CbGbCtD
Fentanyl—CYP3A4—Etoposide—hematologic cancer	0.00166	0.005	CbGbCtD
Fentanyl—CYP3A4—Dexamethasone—hematologic cancer	0.00136	0.00411	CbGbCtD
Fentanyl—CYP3A4—Doxorubicin—hematologic cancer	0.00113	0.00341	CbGbCtD
Fentanyl—Benazepril—MTHFR—hematologic cancer	0.000147	0.233	CrCbGaD
Fentanyl—Phenoxybenzamine—SLC22A1—hematologic cancer	7.58e-05	0.12	CrCbGaD
Fentanyl—Alfentanil—ALB—hematologic cancer	7.45e-05	0.118	CrCbGaD
Fentanyl—Alfentanil—ABCB1—hematologic cancer	7.11e-05	0.113	CrCbGaD
Fentanyl—Diphenhydramine—SLC22A1—hematologic cancer	6.36e-05	0.101	CrCbGaD
Fentanyl—Astemizole—ABCB1—hematologic cancer	5.53e-05	0.0878	CrCbGaD
Fentanyl—Fexofenadine—ABCB1—hematologic cancer	3.94e-05	0.0625	CrCbGaD
Fentanyl—Propafenone—ABCB1—hematologic cancer	3.17e-05	0.0504	CrCbGaD
Fentanyl—Bepridil—ABCB1—hematologic cancer	2.83e-05	0.0449	CrCbGaD
Fentanyl—Loperamide—ABCB1—hematologic cancer	2.51e-05	0.0398	CrCbGaD
Fentanyl—Methadone—ABCB1—hematologic cancer	1.78e-05	0.0283	CrCbGaD
Fentanyl—Flatulence—Epirubicin—hematologic cancer	7.04e-06	3.76e-05	CcSEcCtD
Fentanyl—Tension—Epirubicin—hematologic cancer	7.01e-06	3.74e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Dexamethasone—hematologic cancer	7e-06	3.74e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Betamethasone—hematologic cancer	7e-06	3.74e-05	CcSEcCtD
Fentanyl—Dysgeusia—Epirubicin—hematologic cancer	6.99e-06	3.73e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Triamcinolone—hematologic cancer	6.95e-06	3.71e-05	CcSEcCtD
Fentanyl—Nervousness—Epirubicin—hematologic cancer	6.93e-06	3.7e-05	CcSEcCtD
Fentanyl—Back pain—Epirubicin—hematologic cancer	6.91e-06	3.69e-05	CcSEcCtD
Fentanyl—Angiopathy—Doxorubicin—hematologic cancer	6.89e-06	3.68e-05	CcSEcCtD
Fentanyl—Malaise—Methotrexate—hematologic cancer	6.88e-06	3.67e-05	CcSEcCtD
Fentanyl—Dizziness—Etoposide—hematologic cancer	6.87e-06	3.67e-05	CcSEcCtD
Fentanyl—Muscle spasms—Epirubicin—hematologic cancer	6.86e-06	3.67e-05	CcSEcCtD
Fentanyl—Immune system disorder—Doxorubicin—hematologic cancer	6.85e-06	3.66e-05	CcSEcCtD
Fentanyl—Vertigo—Methotrexate—hematologic cancer	6.85e-06	3.66e-05	CcSEcCtD
Fentanyl—Mediastinal disorder—Doxorubicin—hematologic cancer	6.84e-06	3.65e-05	CcSEcCtD
Fentanyl—Leukopenia—Methotrexate—hematologic cancer	6.83e-06	3.65e-05	CcSEcCtD
Fentanyl—Chills—Doxorubicin—hematologic cancer	6.81e-06	3.64e-05	CcSEcCtD
Fentanyl—Urticaria—Dexamethasone—hematologic cancer	6.8e-06	3.63e-05	CcSEcCtD
Fentanyl—Urticaria—Betamethasone—hematologic cancer	6.8e-06	3.63e-05	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.79e-06	3.62e-05	CcSEcCtD
Fentanyl—Dizziness—Prednisolone—hematologic cancer	6.78e-06	3.62e-05	CcSEcCtD
Fentanyl—Arrhythmia—Doxorubicin—hematologic cancer	6.78e-06	3.62e-05	CcSEcCtD
Fentanyl—Asthenia—Triamcinolone—hematologic cancer	6.76e-06	3.61e-05	CcSEcCtD
Fentanyl—Abdominal pain—Dexamethasone—hematologic cancer	6.76e-06	3.61e-05	CcSEcCtD
Fentanyl—Body temperature increased—Betamethasone—hematologic cancer	6.76e-06	3.61e-05	CcSEcCtD
Fentanyl—Abdominal pain—Betamethasone—hematologic cancer	6.76e-06	3.61e-05	CcSEcCtD
Fentanyl—Body temperature increased—Dexamethasone—hematologic cancer	6.76e-06	3.61e-05	CcSEcCtD
Fentanyl—Nausea—Cisplatin—hematologic cancer	6.74e-06	3.6e-05	CcSEcCtD
Fentanyl—Insomnia—Prednisone—hematologic cancer	6.74e-06	3.6e-05	CcSEcCtD
Fentanyl—Vision blurred—Epirubicin—hematologic cancer	6.73e-06	3.59e-05	CcSEcCtD
Fentanyl—Alopecia—Doxorubicin—hematologic cancer	6.71e-06	3.58e-05	CcSEcCtD
Fentanyl—Paraesthesia—Prednisone—hematologic cancer	6.69e-06	3.57e-05	CcSEcCtD
Fentanyl—Pruritus—Triamcinolone—hematologic cancer	6.67e-06	3.56e-05	CcSEcCtD
Fentanyl—Cough—Methotrexate—hematologic cancer	6.66e-06	3.56e-05	CcSEcCtD
Fentanyl—Mental disorder—Doxorubicin—hematologic cancer	6.65e-06	3.55e-05	CcSEcCtD
Fentanyl—Ill-defined disorder—Epirubicin—hematologic cancer	6.62e-06	3.54e-05	CcSEcCtD
Fentanyl—Convulsion—Methotrexate—hematologic cancer	6.61e-06	3.53e-05	CcSEcCtD
Fentanyl—Vomiting—Etoposide—hematologic cancer	6.61e-06	3.53e-05	CcSEcCtD
Fentanyl—Erythema—Doxorubicin—hematologic cancer	6.61e-06	3.53e-05	CcSEcCtD
Fentanyl—Malnutrition—Doxorubicin—hematologic cancer	6.61e-06	3.53e-05	CcSEcCtD
Fentanyl—Anaemia—Epirubicin—hematologic cancer	6.6e-06	3.52e-05	CcSEcCtD
Fentanyl—Agitation—Epirubicin—hematologic cancer	6.56e-06	3.5e-05	CcSEcCtD
Fentanyl—Dyspepsia—Prednisone—hematologic cancer	6.56e-06	3.5e-05	CcSEcCtD
Fentanyl—Rash—Etoposide—hematologic cancer	6.55e-06	3.5e-05	CcSEcCtD
Fentanyl—Dermatitis—Etoposide—hematologic cancer	6.55e-06	3.5e-05	CcSEcCtD
Fentanyl—Headache—Etoposide—hematologic cancer	6.51e-06	3.48e-05	CcSEcCtD
Fentanyl—Flatulence—Doxorubicin—hematologic cancer	6.51e-06	3.48e-05	CcSEcCtD
Fentanyl—Arthralgia—Methotrexate—hematologic cancer	6.5e-06	3.47e-05	CcSEcCtD
Fentanyl—Myalgia—Methotrexate—hematologic cancer	6.5e-06	3.47e-05	CcSEcCtD
Fentanyl—Chest pain—Methotrexate—hematologic cancer	6.5e-06	3.47e-05	CcSEcCtD
Fentanyl—Tension—Doxorubicin—hematologic cancer	6.48e-06	3.46e-05	CcSEcCtD
Fentanyl—Decreased appetite—Prednisone—hematologic cancer	6.48e-06	3.46e-05	CcSEcCtD
Fentanyl—Dysgeusia—Doxorubicin—hematologic cancer	6.47e-06	3.45e-05	CcSEcCtD
Fentanyl—Rash—Prednisolone—hematologic cancer	6.46e-06	3.45e-05	CcSEcCtD
Fentanyl—Dermatitis—Prednisolone—hematologic cancer	6.46e-06	3.45e-05	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.45e-06	3.44e-05	CcSEcCtD
Fentanyl—Malaise—Epirubicin—hematologic cancer	6.44e-06	3.44e-05	CcSEcCtD
Fentanyl—Fatigue—Prednisone—hematologic cancer	6.42e-06	3.43e-05	CcSEcCtD
Fentanyl—Headache—Prednisolone—hematologic cancer	6.42e-06	3.43e-05	CcSEcCtD
Fentanyl—Discomfort—Methotrexate—hematologic cancer	6.42e-06	3.43e-05	CcSEcCtD
Fentanyl—Nervousness—Doxorubicin—hematologic cancer	6.42e-06	3.43e-05	CcSEcCtD
Fentanyl—Vertigo—Epirubicin—hematologic cancer	6.41e-06	3.43e-05	CcSEcCtD
Fentanyl—Syncope—Epirubicin—hematologic cancer	6.4e-06	3.42e-05	CcSEcCtD
Fentanyl—Leukopenia—Epirubicin—hematologic cancer	6.39e-06	3.41e-05	CcSEcCtD
Fentanyl—Back pain—Doxorubicin—hematologic cancer	6.39e-06	3.41e-05	CcSEcCtD
Fentanyl—Constipation—Prednisone—hematologic cancer	6.37e-06	3.4e-05	CcSEcCtD
Fentanyl—Muscle spasms—Doxorubicin—hematologic cancer	6.35e-06	3.39e-05	CcSEcCtD
Fentanyl—Palpitations—Epirubicin—hematologic cancer	6.31e-06	3.37e-05	CcSEcCtD
Fentanyl—Confusional state—Methotrexate—hematologic cancer	6.28e-06	3.35e-05	CcSEcCtD
Fentanyl—Loss of consciousness—Epirubicin—hematologic cancer	6.28e-06	3.35e-05	CcSEcCtD
Fentanyl—Dizziness—Triamcinolone—hematologic cancer	6.24e-06	3.33e-05	CcSEcCtD
Fentanyl—Cough—Epirubicin—hematologic cancer	6.23e-06	3.33e-05	CcSEcCtD
Fentanyl—Anaphylactic shock—Methotrexate—hematologic cancer	6.23e-06	3.33e-05	CcSEcCtD
Fentanyl—Vision blurred—Doxorubicin—hematologic cancer	6.23e-06	3.32e-05	CcSEcCtD
Fentanyl—Convulsion—Epirubicin—hematologic cancer	6.19e-06	3.3e-05	CcSEcCtD
Fentanyl—Infection—Methotrexate—hematologic cancer	6.19e-06	3.3e-05	CcSEcCtD
Fentanyl—Nausea—Etoposide—hematologic cancer	6.17e-06	3.3e-05	CcSEcCtD
Fentanyl—Hypertension—Epirubicin—hematologic cancer	6.16e-06	3.29e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Prednisone—hematologic cancer	6.14e-06	3.28e-05	CcSEcCtD
Fentanyl—Asthenia—Betamethasone—hematologic cancer	6.14e-06	3.28e-05	CcSEcCtD
Fentanyl—Asthenia—Dexamethasone—hematologic cancer	6.14e-06	3.28e-05	CcSEcCtD
Fentanyl—Ill-defined disorder—Doxorubicin—hematologic cancer	6.13e-06	3.27e-05	CcSEcCtD
Fentanyl—Nervous system disorder—Methotrexate—hematologic cancer	6.11e-06	3.26e-05	CcSEcCtD
Fentanyl—Anaemia—Doxorubicin—hematologic cancer	6.11e-06	3.26e-05	CcSEcCtD
Fentanyl—Thrombocytopenia—Methotrexate—hematologic cancer	6.1e-06	3.26e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Prednisone—hematologic cancer	6.09e-06	3.25e-05	CcSEcCtD
Fentanyl—Nausea—Prednisolone—hematologic cancer	6.09e-06	3.25e-05	CcSEcCtD
Fentanyl—Chest pain—Epirubicin—hematologic cancer	6.08e-06	3.25e-05	CcSEcCtD
Fentanyl—Arthralgia—Epirubicin—hematologic cancer	6.08e-06	3.25e-05	CcSEcCtD
Fentanyl—Myalgia—Epirubicin—hematologic cancer	6.08e-06	3.25e-05	CcSEcCtD
Fentanyl—Agitation—Doxorubicin—hematologic cancer	6.07e-06	3.24e-05	CcSEcCtD
Fentanyl—Anxiety—Epirubicin—hematologic cancer	6.06e-06	3.23e-05	CcSEcCtD
Fentanyl—Pruritus—Betamethasone—hematologic cancer	6.05e-06	3.23e-05	CcSEcCtD
Fentanyl—Pruritus—Dexamethasone—hematologic cancer	6.05e-06	3.23e-05	CcSEcCtD
Fentanyl—Skin disorder—Methotrexate—hematologic cancer	6.05e-06	3.23e-05	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.04e-06	3.22e-05	CcSEcCtD
Fentanyl—Hyperhidrosis—Methotrexate—hematologic cancer	6.02e-06	3.21e-05	CcSEcCtD
Fentanyl—Discomfort—Epirubicin—hematologic cancer	6.01e-06	3.21e-05	CcSEcCtD
Fentanyl—Vomiting—Triamcinolone—hematologic cancer	5.99e-06	3.2e-05	CcSEcCtD
Fentanyl—Malaise—Doxorubicin—hematologic cancer	5.96e-06	3.18e-05	CcSEcCtD
Fentanyl—Rash—Triamcinolone—hematologic cancer	5.94e-06	3.17e-05	CcSEcCtD
Fentanyl—Dry mouth—Epirubicin—hematologic cancer	5.94e-06	3.17e-05	CcSEcCtD
Fentanyl—Dermatitis—Triamcinolone—hematologic cancer	5.94e-06	3.17e-05	CcSEcCtD
Fentanyl—Vertigo—Doxorubicin—hematologic cancer	5.94e-06	3.17e-05	CcSEcCtD
Fentanyl—Anorexia—Methotrexate—hematologic cancer	5.94e-06	3.17e-05	CcSEcCtD
Fentanyl—Syncope—Doxorubicin—hematologic cancer	5.92e-06	3.16e-05	CcSEcCtD
Fentanyl—Urticaria—Prednisone—hematologic cancer	5.92e-06	3.16e-05	CcSEcCtD
Fentanyl—Leukopenia—Doxorubicin—hematologic cancer	5.91e-06	3.16e-05	CcSEcCtD
Fentanyl—Headache—Triamcinolone—hematologic cancer	5.91e-06	3.15e-05	CcSEcCtD
Fentanyl—Body temperature increased—Prednisone—hematologic cancer	5.89e-06	3.15e-05	CcSEcCtD
Fentanyl—Abdominal pain—Prednisone—hematologic cancer	5.89e-06	3.15e-05	CcSEcCtD
Fentanyl—Confusional state—Epirubicin—hematologic cancer	5.88e-06	3.14e-05	CcSEcCtD
Fentanyl—Diarrhoea—Betamethasone—hematologic cancer	5.85e-06	3.13e-05	CcSEcCtD
Fentanyl—Diarrhoea—Dexamethasone—hematologic cancer	5.85e-06	3.13e-05	CcSEcCtD
Fentanyl—Palpitations—Doxorubicin—hematologic cancer	5.84e-06	3.12e-05	CcSEcCtD
Fentanyl—Anaphylactic shock—Epirubicin—hematologic cancer	5.83e-06	3.11e-05	CcSEcCtD
Fentanyl—Oedema—Epirubicin—hematologic cancer	5.83e-06	3.11e-05	CcSEcCtD
Fentanyl—Hypotension—Methotrexate—hematologic cancer	5.82e-06	3.11e-05	CcSEcCtD
Fentanyl—Loss of consciousness—Doxorubicin—hematologic cancer	5.81e-06	3.1e-05	CcSEcCtD
Fentanyl—Infection—Epirubicin—hematologic cancer	5.79e-06	3.09e-05	CcSEcCtD
Fentanyl—Cough—Doxorubicin—hematologic cancer	5.76e-06	3.08e-05	CcSEcCtD
Fentanyl—Shock—Epirubicin—hematologic cancer	5.73e-06	3.06e-05	CcSEcCtD
Fentanyl—Convulsion—Doxorubicin—hematologic cancer	5.72e-06	3.06e-05	CcSEcCtD
Fentanyl—Nervous system disorder—Epirubicin—hematologic cancer	5.71e-06	3.05e-05	CcSEcCtD
Fentanyl—Thrombocytopenia—Epirubicin—hematologic cancer	5.71e-06	3.05e-05	CcSEcCtD
Fentanyl—Hypertension—Doxorubicin—hematologic cancer	5.7e-06	3.05e-05	CcSEcCtD
Fentanyl—Tachycardia—Epirubicin—hematologic cancer	5.69e-06	3.04e-05	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.67e-06	3.03e-05	CcSEcCtD
Fentanyl—Skin disorder—Epirubicin—hematologic cancer	5.66e-06	3.02e-05	CcSEcCtD
Fentanyl—Dizziness—Betamethasone—hematologic cancer	5.66e-06	3.02e-05	CcSEcCtD
Fentanyl—Dizziness—Dexamethasone—hematologic cancer	5.66e-06	3.02e-05	CcSEcCtD
Fentanyl—Hyperhidrosis—Epirubicin—hematologic cancer	5.63e-06	3.01e-05	CcSEcCtD
Fentanyl—Insomnia—Methotrexate—hematologic cancer	5.63e-06	3.01e-05	CcSEcCtD
Fentanyl—Arthralgia—Doxorubicin—hematologic cancer	5.62e-06	3e-05	CcSEcCtD
Fentanyl—Myalgia—Doxorubicin—hematologic cancer	5.62e-06	3e-05	CcSEcCtD
Fentanyl—Chest pain—Doxorubicin—hematologic cancer	5.62e-06	3e-05	CcSEcCtD
Fentanyl—Anxiety—Doxorubicin—hematologic cancer	5.6e-06	2.99e-05	CcSEcCtD
Fentanyl—Nausea—Triamcinolone—hematologic cancer	5.6e-06	2.99e-05	CcSEcCtD
Fentanyl—Paraesthesia—Methotrexate—hematologic cancer	5.59e-06	2.99e-05	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.59e-06	2.98e-05	CcSEcCtD
Fentanyl—Discomfort—Doxorubicin—hematologic cancer	5.56e-06	2.97e-05	CcSEcCtD
Fentanyl—Anorexia—Epirubicin—hematologic cancer	5.55e-06	2.97e-05	CcSEcCtD
Fentanyl—Dyspnoea—Methotrexate—hematologic cancer	5.55e-06	2.96e-05	CcSEcCtD
Fentanyl—Somnolence—Methotrexate—hematologic cancer	5.54e-06	2.96e-05	CcSEcCtD
Fentanyl—Dry mouth—Doxorubicin—hematologic cancer	5.5e-06	2.94e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Prednisone—hematologic cancer	5.49e-06	2.93e-05	CcSEcCtD
Fentanyl—Dyspepsia—Methotrexate—hematologic cancer	5.48e-06	2.93e-05	CcSEcCtD
Fentanyl—Hypotension—Epirubicin—hematologic cancer	5.44e-06	2.91e-05	CcSEcCtD
Fentanyl—Vomiting—Betamethasone—hematologic cancer	5.44e-06	2.9e-05	CcSEcCtD
Fentanyl—Vomiting—Dexamethasone—hematologic cancer	5.44e-06	2.9e-05	CcSEcCtD
Fentanyl—Confusional state—Doxorubicin—hematologic cancer	5.44e-06	2.9e-05	CcSEcCtD
Fentanyl—Decreased appetite—Methotrexate—hematologic cancer	5.41e-06	2.89e-05	CcSEcCtD
Fentanyl—Rash—Dexamethasone—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Rash—Betamethasone—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Anaphylactic shock—Doxorubicin—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Oedema—Doxorubicin—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Dermatitis—Dexamethasone—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Dermatitis—Betamethasone—hematologic cancer	5.39e-06	2.88e-05	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.38e-06	2.87e-05	CcSEcCtD
Fentanyl—Fatigue—Methotrexate—hematologic cancer	5.37e-06	2.87e-05	CcSEcCtD
Fentanyl—Headache—Dexamethasone—hematologic cancer	5.36e-06	2.86e-05	CcSEcCtD
Fentanyl—Headache—Betamethasone—hematologic cancer	5.36e-06	2.86e-05	CcSEcCtD
Fentanyl—Infection—Doxorubicin—hematologic cancer	5.36e-06	2.86e-05	CcSEcCtD
Fentanyl—Asthenia—Prednisone—hematologic cancer	5.35e-06	2.85e-05	CcSEcCtD
Fentanyl—Pain—Methotrexate—hematologic cancer	5.32e-06	2.84e-05	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.31e-06	2.84e-05	CcSEcCtD
Fentanyl—Shock—Doxorubicin—hematologic cancer	5.3e-06	2.83e-05	CcSEcCtD
Fentanyl—Nervous system disorder—Doxorubicin—hematologic cancer	5.29e-06	2.82e-05	CcSEcCtD
Fentanyl—Thrombocytopenia—Doxorubicin—hematologic cancer	5.28e-06	2.82e-05	CcSEcCtD
Fentanyl—Pruritus—Prednisone—hematologic cancer	5.27e-06	2.81e-05	CcSEcCtD
Fentanyl—Insomnia—Epirubicin—hematologic cancer	5.27e-06	2.81e-05	CcSEcCtD
Fentanyl—Tachycardia—Doxorubicin—hematologic cancer	5.26e-06	2.81e-05	CcSEcCtD
Fentanyl—Skin disorder—Doxorubicin—hematologic cancer	5.24e-06	2.8e-05	CcSEcCtD
Fentanyl—Paraesthesia—Epirubicin—hematologic cancer	5.23e-06	2.79e-05	CcSEcCtD
Fentanyl—Hyperhidrosis—Doxorubicin—hematologic cancer	5.21e-06	2.78e-05	CcSEcCtD
Fentanyl—Dyspnoea—Epirubicin—hematologic cancer	5.2e-06	2.77e-05	CcSEcCtD
Fentanyl—Somnolence—Epirubicin—hematologic cancer	5.18e-06	2.77e-05	CcSEcCtD
Fentanyl—Anorexia—Doxorubicin—hematologic cancer	5.14e-06	2.74e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Methotrexate—hematologic cancer	5.13e-06	2.74e-05	CcSEcCtD
Fentanyl—Dyspepsia—Epirubicin—hematologic cancer	5.13e-06	2.74e-05	CcSEcCtD
Fentanyl—Diarrhoea—Prednisone—hematologic cancer	5.1e-06	2.72e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methotrexate—hematologic cancer	5.09e-06	2.72e-05	CcSEcCtD
Fentanyl—Nausea—Betamethasone—hematologic cancer	5.08e-06	2.71e-05	CcSEcCtD
Fentanyl—Nausea—Dexamethasone—hematologic cancer	5.08e-06	2.71e-05	CcSEcCtD
Fentanyl—Decreased appetite—Epirubicin—hematologic cancer	5.07e-06	2.71e-05	CcSEcCtD
Fentanyl—Hypotension—Doxorubicin—hematologic cancer	5.04e-06	2.69e-05	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.03e-06	2.69e-05	CcSEcCtD
Fentanyl—Fatigue—Epirubicin—hematologic cancer	5.02e-06	2.68e-05	CcSEcCtD
Fentanyl—Pain—Epirubicin—hematologic cancer	4.98e-06	2.66e-05	CcSEcCtD
Fentanyl—Constipation—Epirubicin—hematologic cancer	4.98e-06	2.66e-05	CcSEcCtD
Fentanyl—Urticaria—Methotrexate—hematologic cancer	4.95e-06	2.64e-05	CcSEcCtD
Fentanyl—Dizziness—Prednisone—hematologic cancer	4.93e-06	2.63e-05	CcSEcCtD
Fentanyl—Abdominal pain—Methotrexate—hematologic cancer	4.92e-06	2.63e-05	CcSEcCtD
Fentanyl—Body temperature increased—Methotrexate—hematologic cancer	4.92e-06	2.63e-05	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.91e-06	2.62e-05	CcSEcCtD
Fentanyl—Insomnia—Doxorubicin—hematologic cancer	4.88e-06	2.6e-05	CcSEcCtD
Fentanyl—Paraesthesia—Doxorubicin—hematologic cancer	4.84e-06	2.59e-05	CcSEcCtD
Fentanyl—Dyspnoea—Doxorubicin—hematologic cancer	4.81e-06	2.57e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Epirubicin—hematologic cancer	4.8e-06	2.56e-05	CcSEcCtD
Fentanyl—Somnolence—Doxorubicin—hematologic cancer	4.79e-06	2.56e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Epirubicin—hematologic cancer	4.76e-06	2.54e-05	CcSEcCtD
Fentanyl—Dyspepsia—Doxorubicin—hematologic cancer	4.75e-06	2.53e-05	CcSEcCtD
Fentanyl—Vomiting—Prednisone—hematologic cancer	4.74e-06	2.53e-05	CcSEcCtD
Fentanyl—Rash—Prednisone—hematologic cancer	4.7e-06	2.51e-05	CcSEcCtD
Fentanyl—Dermatitis—Prednisone—hematologic cancer	4.69e-06	2.51e-05	CcSEcCtD
Fentanyl—Decreased appetite—Doxorubicin—hematologic cancer	4.69e-06	2.5e-05	CcSEcCtD
Fentanyl—Headache—Prednisone—hematologic cancer	4.67e-06	2.49e-05	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.65e-06	2.49e-05	CcSEcCtD
Fentanyl—Fatigue—Doxorubicin—hematologic cancer	4.65e-06	2.48e-05	CcSEcCtD
Fentanyl—Urticaria—Epirubicin—hematologic cancer	4.63e-06	2.47e-05	CcSEcCtD
Fentanyl—Pain—Doxorubicin—hematologic cancer	4.61e-06	2.46e-05	CcSEcCtD
Fentanyl—Constipation—Doxorubicin—hematologic cancer	4.61e-06	2.46e-05	CcSEcCtD
Fentanyl—Abdominal pain—Epirubicin—hematologic cancer	4.61e-06	2.46e-05	CcSEcCtD
Fentanyl—Body temperature increased—Epirubicin—hematologic cancer	4.61e-06	2.46e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Methotrexate—hematologic cancer	4.59e-06	2.45e-05	CcSEcCtD
Fentanyl—Asthenia—Methotrexate—hematologic cancer	4.47e-06	2.39e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Doxorubicin—hematologic cancer	4.44e-06	2.37e-05	CcSEcCtD
Fentanyl—Nausea—Prednisone—hematologic cancer	4.43e-06	2.36e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.41e-06	2.35e-05	CcSEcCtD
Fentanyl—Pruritus—Methotrexate—hematologic cancer	4.41e-06	2.35e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Epirubicin—hematologic cancer	4.29e-06	2.29e-05	CcSEcCtD
Fentanyl—Urticaria—Doxorubicin—hematologic cancer	4.28e-06	2.29e-05	CcSEcCtD
Fentanyl—Abdominal pain—Doxorubicin—hematologic cancer	4.26e-06	2.28e-05	CcSEcCtD
Fentanyl—Body temperature increased—Doxorubicin—hematologic cancer	4.26e-06	2.28e-05	CcSEcCtD
Fentanyl—Diarrhoea—Methotrexate—hematologic cancer	4.26e-06	2.28e-05	CcSEcCtD
Fentanyl—Asthenia—Epirubicin—hematologic cancer	4.18e-06	2.23e-05	CcSEcCtD
Fentanyl—Pruritus—Epirubicin—hematologic cancer	4.12e-06	2.2e-05	CcSEcCtD
Fentanyl—Dizziness—Methotrexate—hematologic cancer	4.12e-06	2.2e-05	CcSEcCtD
Fentanyl—Diarrhoea—Epirubicin—hematologic cancer	3.99e-06	2.13e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Doxorubicin—hematologic cancer	3.97e-06	2.12e-05	CcSEcCtD
Fentanyl—Vomiting—Methotrexate—hematologic cancer	3.96e-06	2.11e-05	CcSEcCtD
Fentanyl—Rash—Methotrexate—hematologic cancer	3.93e-06	2.1e-05	CcSEcCtD
Fentanyl—Dermatitis—Methotrexate—hematologic cancer	3.92e-06	2.09e-05	CcSEcCtD
Fentanyl—Headache—Methotrexate—hematologic cancer	3.9e-06	2.08e-05	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—ESR1—hematologic cancer	3.9e-06	0.000122	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CREBBP—hematologic cancer	3.89e-06	0.000122	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ABCG2—hematologic cancer	3.88e-06	0.000122	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—MTR—hematologic cancer	3.88e-06	0.000122	CbGpPWpGaD
Fentanyl—Asthenia—Doxorubicin—hematologic cancer	3.87e-06	2.07e-05	CcSEcCtD
Fentanyl—Dizziness—Epirubicin—hematologic cancer	3.85e-06	2.06e-05	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—FN1—hematologic cancer	3.85e-06	0.000121	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CYCS—hematologic cancer	3.85e-06	0.000121	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	3.82e-06	0.00012	CbGpPWpGaD
Fentanyl—Pruritus—Doxorubicin—hematologic cancer	3.81e-06	2.04e-05	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—MTHFR—hematologic cancer	3.81e-06	0.000119	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ENO2—hematologic cancer	3.81e-06	0.000119	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NFKBIA—hematologic cancer	3.8e-06	0.000119	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—BAD—hematologic cancer	3.8e-06	0.000119	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NOTCH1—hematologic cancer	3.77e-06	0.000118	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2RA—hematologic cancer	3.74e-06	0.000117	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MAP2K1—hematologic cancer	3.72e-06	0.000116	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—FHL2—hematologic cancer	3.71e-06	0.000116	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL2—hematologic cancer	3.71e-06	0.000116	CbGpPWpGaD
Fentanyl—Vomiting—Epirubicin—hematologic cancer	3.7e-06	1.98e-05	CcSEcCtD
Fentanyl—Nausea—Methotrexate—hematologic cancer	3.7e-06	1.98e-05	CcSEcCtD
Fentanyl—OPRM1—Signaling Pathways—TERT—hematologic cancer	3.69e-06	0.000116	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PIK3CD—hematologic cancer	3.69e-06	0.000116	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTT1—hematologic cancer	3.69e-06	0.000116	CbGpPWpGaD
Fentanyl—Diarrhoea—Doxorubicin—hematologic cancer	3.69e-06	1.97e-05	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—CD80—hematologic cancer	3.69e-06	0.000116	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PIK3CG—hematologic cancer	3.68e-06	0.000115	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—KIT—hematologic cancer	3.68e-06	0.000115	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—NRAS—hematologic cancer	3.68e-06	0.000115	CbGpPWpGaD
Fentanyl—Rash—Epirubicin—hematologic cancer	3.67e-06	1.96e-05	CcSEcCtD
Fentanyl—Dermatitis—Epirubicin—hematologic cancer	3.67e-06	1.96e-05	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.66e-06	0.000115	CbGpPWpGaD
Fentanyl—Headache—Epirubicin—hematologic cancer	3.65e-06	1.95e-05	CcSEcCtD
Fentanyl—CYP3A4—Metabolism—AGRN—hematologic cancer	3.64e-06	0.000114	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PTPN11—hematologic cancer	3.62e-06	0.000113	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—KRAS—hematologic cancer	3.61e-06	0.000113	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—SDC1—hematologic cancer	3.61e-06	0.000113	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PDGFB—hematologic cancer	3.61e-06	0.000113	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	3.58e-06	0.000112	CbGpPWpGaD
Fentanyl—Dizziness—Doxorubicin—hematologic cancer	3.57e-06	1.9e-05	CcSEcCtD
Fentanyl—OPRD1—Signaling Pathways—FGF2—hematologic cancer	3.53e-06	0.000111	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—MAPK3—hematologic cancer	3.53e-06	0.00011	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TSC2—hematologic cancer	3.52e-06	0.00011	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CREB1—hematologic cancer	3.5e-06	0.00011	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PIK3R1—hematologic cancer	3.49e-06	0.000109	CbGpPWpGaD
Fentanyl—Nausea—Epirubicin—hematologic cancer	3.46e-06	1.85e-05	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—BRAF—hematologic cancer	3.46e-06	0.000108	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.46e-06	0.000108	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—IDH2—hematologic cancer	3.45e-06	0.000108	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—HMMR—hematologic cancer	3.45e-06	0.000108	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL2—hematologic cancer	3.43e-06	0.000107	CbGpPWpGaD
Fentanyl—Vomiting—Doxorubicin—hematologic cancer	3.43e-06	1.83e-05	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—IL6R—hematologic cancer	3.42e-06	0.000107	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CREBBP—hematologic cancer	3.41e-06	0.000107	CbGpPWpGaD
Fentanyl—Rash—Doxorubicin—hematologic cancer	3.4e-06	1.82e-05	CcSEcCtD
Fentanyl—Dermatitis—Doxorubicin—hematologic cancer	3.4e-06	1.81e-05	CcSEcCtD
Fentanyl—CYP3A5—Metabolism—GSTP1—hematologic cancer	3.39e-06	0.000106	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—FGFR3—hematologic cancer	3.39e-06	0.000106	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—JAK2—hematologic cancer	3.39e-06	0.000106	CbGpPWpGaD
Fentanyl—Headache—Doxorubicin—hematologic cancer	3.38e-06	1.8e-05	CcSEcCtD
Fentanyl—OPRM1—Signaling Pathways—MAPK14—hematologic cancer	3.36e-06	0.000105	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—PIK3CA—hematologic cancer	3.32e-06	0.000104	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MDM2—hematologic cancer	3.31e-06	0.000104	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—ESR1—hematologic cancer	3.29e-06	0.000103	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MAP2K1—hematologic cancer	3.26e-06	0.000102	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—FN1—hematologic cancer	3.25e-06	0.000102	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.24e-06	0.000102	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PIK3CD—hematologic cancer	3.24e-06	0.000101	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.23e-06	0.000101	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MTOR—hematologic cancer	3.22e-06	0.000101	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PIK3CB—hematologic cancer	3.22e-06	0.000101	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—BAD—hematologic cancer	3.21e-06	0.000101	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NFKBIA—hematologic cancer	3.21e-06	0.000101	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ABCB1—hematologic cancer	3.21e-06	0.000101	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.21e-06	0.0001	CbGpPWpGaD
Fentanyl—Nausea—Doxorubicin—hematologic cancer	3.2e-06	1.71e-05	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—PIK3CG—hematologic cancer	3.2e-06	0.0001	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NOTCH1—hematologic cancer	3.18e-06	9.97e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—KRAS—hematologic cancer	3.17e-06	9.93e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CA9—hematologic cancer	3.16e-06	9.88e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ACP5—hematologic cancer	3.16e-06	9.88e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CD80—hematologic cancer	3.12e-06	9.77e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTM1—hematologic cancer	3.12e-06	9.76e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NCOR1—hematologic cancer	3.12e-06	9.76e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.11e-06	9.76e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—KIT—hematologic cancer	3.11e-06	9.75e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PIK3CG—hematologic cancer	3.11e-06	9.75e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—NRAS—hematologic cancer	3.11e-06	9.75e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—FGF2—hematologic cancer	3.1e-06	9.71e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—HRAS—hematologic cancer	3.07e-06	9.62e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NQO1—hematologic cancer	3.07e-06	9.61e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CD44—hematologic cancer	3.07e-06	9.61e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PTPN11—hematologic cancer	3.06e-06	9.58e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PIK3R1—hematologic cancer	3.06e-06	9.58e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CDKN1B—hematologic cancer	3.02e-06	9.46e-05	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—AKT1—hematologic cancer	2.99e-06	9.36e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—MAPK3—hematologic cancer	2.98e-06	9.34e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—JAK2—hematologic cancer	2.97e-06	9.31e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CREBBP—hematologic cancer	2.97e-06	9.3e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—IDH1—hematologic cancer	2.97e-06	9.29e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CREB1—hematologic cancer	2.96e-06	9.28e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CASP3—hematologic cancer	2.96e-06	9.27e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL2—hematologic cancer	2.95e-06	9.26e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL6—hematologic cancer	2.94e-06	9.21e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—TXN—hematologic cancer	2.93e-06	9.19e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.93e-06	9.19e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.93e-06	9.19e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—BRAF—hematologic cancer	2.93e-06	9.16e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—PIK3CA—hematologic cancer	2.91e-06	9.12e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CYCS—hematologic cancer	2.9e-06	9.09e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MDM2—hematologic cancer	2.9e-06	9.09e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL2—hematologic cancer	2.9e-06	9.08e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL6R—hematologic cancer	2.89e-06	9.05e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CREBBP—hematologic cancer	2.89e-06	9.04e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—HSP90AA1—hematologic cancer	2.88e-06	9.04e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCND1—hematologic cancer	2.88e-06	9.03e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—JUN—hematologic cancer	2.87e-06	9.01e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.87e-06	8.99e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PIK3CB—hematologic cancer	2.82e-06	8.84e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MTOR—hematologic cancer	2.82e-06	8.84e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PIK3CD—hematologic cancer	2.81e-06	8.82e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CDKN1A—hematologic cancer	2.79e-06	8.73e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PTEN—hematologic cancer	2.78e-06	8.71e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—ALB—hematologic cancer	2.78e-06	8.7e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.76e-06	8.64e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.75e-06	8.63e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—MTHFR—hematologic cancer	2.75e-06	8.63e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.74e-06	8.57e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MAPK8—hematologic cancer	2.72e-06	8.52e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—AKT1—hematologic cancer	2.71e-06	8.5e-05	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.71e-06	8.49e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—HRAS—hematologic cancer	2.69e-06	8.44e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.68e-06	8.4e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.68e-06	8.4e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	2.68e-06	8.39e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PIK3R1—hematologic cancer	2.66e-06	8.32e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—EP300—hematologic cancer	2.65e-06	8.31e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CDKN1B—hematologic cancer	2.65e-06	8.3e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—FGF2—hematologic cancer	2.62e-06	8.21e-05	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—AKT1—hematologic cancer	2.62e-06	8.21e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.61e-06	8.19e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CASP3—hematologic cancer	2.6e-06	8.13e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL2—hematologic cancer	2.59e-06	8.12e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.58e-06	8.09e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—SRC—hematologic cancer	2.58e-06	8.08e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL6—hematologic cancer	2.58e-06	8.08e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTP1—hematologic cancer	2.56e-06	8.02e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NUP98—hematologic cancer	2.53e-06	7.93e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCND1—hematologic cancer	2.53e-06	7.91e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—JUN—hematologic cancer	2.52e-06	7.9e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—VEGFA—hematologic cancer	2.51e-06	7.87e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—JAK2—hematologic cancer	2.51e-06	7.87e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—STAT3—hematologic cancer	2.49e-06	7.79e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—NRAS—hematologic cancer	2.48e-06	7.77e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.46e-06	7.71e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.46e-06	7.7e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.46e-06	7.7e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PIK3CB—hematologic cancer	2.45e-06	7.68e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MDM2—hematologic cancer	2.45e-06	7.68e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CDKN1A—hematologic cancer	2.44e-06	7.66e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NUP214—hematologic cancer	2.44e-06	7.65e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PTEN—hematologic cancer	2.44e-06	7.64e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—MTR—hematologic cancer	2.39e-06	7.49e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.39e-06	7.49e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MAPK8—hematologic cancer	2.39e-06	7.47e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.38e-06	7.47e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MTOR—hematologic cancer	2.38e-06	7.47e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—AKT1—hematologic cancer	2.38e-06	7.45e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MAPK3—hematologic cancer	2.38e-06	7.44e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTM1—hematologic cancer	2.35e-06	7.37e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NCOR1—hematologic cancer	2.35e-06	7.37e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ENO2—hematologic cancer	2.34e-06	7.35e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—EP300—hematologic cancer	2.33e-06	7.28e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.31e-06	7.25e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MYC—hematologic cancer	2.31e-06	7.24e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TGFB1—hematologic cancer	2.3e-06	7.22e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	2.28e-06	7.13e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.27e-06	7.13e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—SRC—hematologic cancer	2.26e-06	7.08e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.24e-06	7.01e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—SDC1—hematologic cancer	2.22e-06	6.96e-05	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.21e-06	6.94e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—VEGFA—hematologic cancer	2.2e-06	6.9e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CASP3—hematologic cancer	2.19e-06	6.87e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2—hematologic cancer	2.19e-06	6.86e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—STAT3—hematologic cancer	2.18e-06	6.83e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL6—hematologic cancer	2.18e-06	6.83e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NRAS—hematologic cancer	2.18e-06	6.81e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.15e-06	6.72e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—KRAS—hematologic cancer	2.13e-06	6.69e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCND1—hematologic cancer	2.13e-06	6.69e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—JUN—hematologic cancer	2.13e-06	6.67e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PTEN—hematologic cancer	2.12e-06	6.64e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MAPK3—hematologic cancer	2.08e-06	6.53e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—MTHFR—hematologic cancer	2.08e-06	6.51e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	2.07e-06	6.47e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PTEN—hematologic cancer	2.06e-06	6.46e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.03e-06	6.37e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MYC—hematologic cancer	2.03e-06	6.35e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—EP300—hematologic cancer	2.02e-06	6.33e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TGFB1—hematologic cancer	2.02e-06	6.33e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	2.02e-06	6.32e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	2.01e-06	6.3e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ALB—hematologic cancer	2.01e-06	6.29e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—EP300—hematologic cancer	1.97e-06	6.16e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PIK3CA—hematologic cancer	1.96e-06	6.15e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.92e-06	6.02e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—SRC—hematologic cancer	1.91e-06	5.99e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TP53—hematologic cancer	1.9e-06	5.95e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CD44—hematologic cancer	1.89e-06	5.92e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NQO1—hematologic cancer	1.89e-06	5.92e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—KRAS—hematologic cancer	1.87e-06	5.87e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	1.86e-06	5.83e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—STAT3—hematologic cancer	1.84e-06	5.77e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NRAS—hematologic cancer	1.84e-06	5.76e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—HRAS—hematologic cancer	1.81e-06	5.69e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CYCS—hematologic cancer	1.79e-06	5.6e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.78e-06	5.57e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.77e-06	5.55e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	1.76e-06	5.52e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.75e-06	5.47e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL6—hematologic cancer	1.74e-06	5.44e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	1.72e-06	5.39e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MYC—hematologic cancer	1.71e-06	5.36e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	1.71e-06	5.35e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TP53—hematologic cancer	1.66e-06	5.21e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CREBBP—hematologic cancer	1.62e-06	5.07e-05	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—AKT1—hematologic cancer	1.6e-06	5.02e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—HRAS—hematologic cancer	1.59e-06	4.99e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—KRAS—hematologic cancer	1.58e-06	4.96e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.58e-06	4.94e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.53e-06	4.81e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PTEN—hematologic cancer	1.53e-06	4.8e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL6—hematologic cancer	1.52e-06	4.77e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ALB—hematologic cancer	1.52e-06	4.75e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.5e-06	4.68e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.49e-06	4.68e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—EP300—hematologic cancer	1.46e-06	4.58e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	4.55e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.45e-06	4.54e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.45e-06	4.54e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.45e-06	4.54e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TP53—hematologic cancer	1.41e-06	4.41e-05	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—AKT1—hematologic cancer	1.41e-06	4.4e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	4.21e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.34e-06	4.19e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL6—hematologic cancer	1.29e-06	4.03e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.28e-06	4.01e-05	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—AKT1—hematologic cancer	1.22e-06	3.83e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—AKT1—hematologic cancer	1.19e-06	3.72e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PTEN—hematologic cancer	1.16e-06	3.62e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—EP300—hematologic cancer	1.1e-06	3.45e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.08e-06	3.39e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.08e-06	3.37e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.97e-07	3.12e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PIK3CD—hematologic cancer	9.46e-07	2.96e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ALB—hematologic cancer	9.33e-07	2.92e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.93e-07	2.8e-05	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—AKT1—hematologic cancer	8.83e-07	2.77e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.24e-07	2.58e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PIK3CA—hematologic cancer	8.16e-07	2.56e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PTEN—hematologic cancer	7.12e-07	2.23e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—EP300—hematologic cancer	6.79e-07	2.13e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—AKT1—hematologic cancer	6.66e-07	2.09e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.02e-07	1.57e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—AKT1—hematologic cancer	4.1e-07	1.29e-05	CbGpPWpGaD
